DE2801867A1 - Antikoagulans-arzneimittel auf der basis von heparin - Google Patents
Antikoagulans-arzneimittel auf der basis von heparinInfo
- Publication number
- DE2801867A1 DE2801867A1 DE19782801867 DE2801867A DE2801867A1 DE 2801867 A1 DE2801867 A1 DE 2801867A1 DE 19782801867 DE19782801867 DE 19782801867 DE 2801867 A DE2801867 A DE 2801867A DE 2801867 A1 DE2801867 A1 DE 2801867A1
- Authority
- DE
- Germany
- Prior art keywords
- heparin
- medicament according
- agent
- aerosol
- thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 34
- 229960002897 heparin Drugs 0.000 title claims description 34
- 229920000669 heparin Polymers 0.000 title claims description 34
- 229940126601 medicinal product Drugs 0.000 title description 2
- 239000003814 drug Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 239000000443 aerosol Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 4
- 230000000510 mucolytic effect Effects 0.000 claims description 4
- 230000002381 testicular Effects 0.000 claims description 4
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- 206010014513 Embolism arterial Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 108010032809 mucopolysaccharidase Proteins 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- SXFPNMRWIWIAGS-UHFFFAOYSA-N Khellin Natural products COC1C2CCOC2C(OC)C3OC(C)CC(=O)C13 SXFPNMRWIWIAGS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- HSMPDPBYAYSOBC-UHFFFAOYSA-N khellin Chemical compound O1C(C)=CC(=O)C2=C1C(OC)=C1OC=CC1=C2OC HSMPDPBYAYSOBC-UHFFFAOYSA-N 0.000 description 1
- 229960002801 khellin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7636431A FR2372632A1 (fr) | 1976-12-03 | 1976-12-03 | Nouveau medicament a base d'heparine administrable par voie tracheo-bronchique et alveolaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2801867A1 true DE2801867A1 (de) | 1979-07-19 |
Family
ID=9180598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19782801867 Withdrawn DE2801867A1 (de) | 1976-12-03 | 1978-01-17 | Antikoagulans-arzneimittel auf der basis von heparin |
Country Status (6)
| Country | Link |
|---|---|
| BE (1) | BE862538A (enExample) |
| DE (1) | DE2801867A1 (enExample) |
| FR (1) | FR2372632A1 (enExample) |
| GB (1) | GB1560463A (enExample) |
| LU (1) | LU78829A1 (enExample) |
| NL (1) | NL7800230A (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4679555A (en) * | 1984-08-07 | 1987-07-14 | Key Pharmaceuticals, Inc. | Method and apparatus for intrapulmonary delivery of heparin |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| AU2003205898A1 (en) * | 2002-02-18 | 2003-09-04 | University Of Southampton | Combination therapy for respiratory disorders |
| AU2003245794A1 (en) * | 2002-02-18 | 2003-09-04 | University Of Southampton | Glycosaminoglycan-dnase combination therapy |
| CN115629048B (zh) * | 2022-10-26 | 2025-12-09 | 上海执诚生物科技有限公司 | 一种抗肝素干扰的丙氨酸氨基转移酶检测试剂盒及其应用 |
-
1976
- 1976-12-03 FR FR7636431A patent/FR2372632A1/fr active Granted
-
1977
- 1977-12-30 BE BE184021A patent/BE862538A/xx unknown
-
1978
- 1978-01-06 GB GB55078A patent/GB1560463A/en not_active Expired
- 1978-01-06 LU LU78829A patent/LU78829A1/xx unknown
- 1978-01-09 NL NL7800230A patent/NL7800230A/xx not_active Application Discontinuation
- 1978-01-17 DE DE19782801867 patent/DE2801867A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BE862538A (fr) | 1978-06-30 |
| GB1560463A (en) | 1980-02-06 |
| NL7800230A (nl) | 1979-07-11 |
| FR2372632B1 (enExample) | 1979-03-23 |
| FR2372632A1 (fr) | 1978-06-30 |
| LU78829A1 (fr) | 1978-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69713485T2 (de) | Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie | |
| EP0065747B1 (de) | Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| EP0200155B1 (de) | Wässrige Chloritmatrix-Lösung | |
| DE10197266T5 (de) | Verfahren zur örtlichen Betäubung und Schmerzstillung | |
| DE2036114B2 (de) | Wäßriges Tetramisolpräparat | |
| EP0125634A1 (de) | Verwendung einer sekretolytisch wirkenden Substanz zur Herstellung eines Antischnarchmittels und zur Bekämpfung des Schnarchphänomens | |
| EP0185210A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| CH662734A5 (de) | Antischnarchmittel. | |
| DE69328792T2 (de) | Behandlung von migräne | |
| DE2206570C3 (de) | Verwendung von (+)-Catechin | |
| DE69937574T2 (de) | Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen | |
| DE2801867A1 (de) | Antikoagulans-arzneimittel auf der basis von heparin | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE69030584T2 (de) | Verfahren sowie zusammensetzungen zur behandlung mit vitaminmineral | |
| DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
| EP0817623B1 (de) | Arzneistoffe zur selektiven bekämpfung von tumorgewebe | |
| DE69227324T2 (de) | Pharmazeutische zusammensetzung, die carbachol und andere cholinerge substanzen enthält | |
| DE602004007304T2 (de) | Verwendung von N2O zur Behandlung von postischemischen cerebralen zellulären Beschädigungen | |
| DE102007014375A1 (de) | Oleylphosphocholin | |
| EP0204737B1 (de) | Präparat zur intramuskulären injektion von medikamenten, vitaminen oder impfstoffen | |
| DE60036790T2 (de) | Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion | |
| DE2036113C3 (de) | Wäßriges Tetramisolpräparat | |
| DE69315840T2 (de) | Verfahren zur verabreichung einer lösung von granulozyten-kolonie-stimulierendem faktor | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |